Pfizer: drug fails in clinical trial

(CercleFinance.com) - Pfizer said on Friday that it is "disappointed" with the results of a phase III study to evaluate the efficacy of a new treatment for sickle cell anemia and associated vaso-occlusive attacks.


According to the US pharmaceutical giant, the results of the clinical trials showed that the treatment did not reach its primary endpoint, measured by the length of time patients were hospitalised.

Sickle cell anemia is a genetic disease of the blood that causes severe pain and vaso-occlusive attacks (obstruction of blood circulation) for which there are currently only a small number of therapeutic leads.


Copyright (c) 2019 CercleFinance.com. All rights reserved.